Showing 672 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

Pharmaceutical industry

GSK and Gilead go head to head as HIV drugs enter new phase

Editor's pick
Reuters
2 November 2017
Confidentiality, consent & medical ethics

DC biohackers and blockchainers take on HIV

Editor's pick
Technical.ly DC
1 November 2017
Resistance

Antibody-Based HIV Tx Proves Durable

Editor's pick
MedPage Today
10 October 2017
New & experimental HIV treatments

Bictegravir-Containing Regimen Found to Be Non-Inferior to Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adult Patients with HIV

Editor's pick
Gilead press release
4 October 2017
Access to healthcare

The Medicines Patent Pool and Gilead Sciences Sign Licence for Bictegravir

Editor's pick
Medicines Patent Pool
4 October 2017
New & experimental HIV treatments

Promising HIV Treatments in Late-Stage Clinical Development

Editor's pick
P&T Community
2 October 2017
Access to healthcare

Single-pill HIV treatment to save SA R11bn – health ministry

Editor's pick
News24
25 September 2017
Access to healthcare

New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low-and middle-income countries at reduced price

Editor's pick
UNAIDS
22 September 2017
New & experimental HIV treatments

Immune 'Cocktails' Likely Needed in HIV

Editor's pick
MedPage Today HIV/AIDS
21 September 2017
New & experimental HIV treatments

Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV

Editor's pick
Business Wire
21 July 2017
New & experimental HIV treatments

The 2017 Pipeline Report

Editor's pick
Treatment Action Group
19 July 2017
Access to healthcare

Dolutegavir access in the Asia-Pacific region

Editor's pick
amfAR Treat Asia
27 June 2017
New & experimental HIV treatments

ViiV Healthcare Files Regulatory Submissions for First Two-Drug HIV Maintenance Regimen

Editor's pick
ViiV
2 June 2017
Pharmaceutical industry

Gilead and GSK go head-to-head with similar HIV drug data

Editor's pick
Reuters
31 May 2017
New & experimental HIV treatments

Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies

Editor's pick
Gilead press release
30 May 2017
New & experimental HIV treatments

Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS® (raltegravir) 600 mg in the European Union

Editor's pick
Merck press release
22 May 2017
Pharmaceutical industry

CHMP recommends for approval generic version of Atripla

Editor's pick
EATG
22 May 2017
Pharmaceutical industry

Gilead's last chronic HIV drug — and what it plans to do now

Editor's pick
San Francisco Business Times
11 May 2017
New & experimental HIV treatments

Orphan Drug Designation for CytoDyn's PRO 140 Declined by the FDA

Editor's pick
Cytodyn press release
18 April 2017
Cardiovascular disease

New antibody therapy “profoundly” successful at reducing inflammation from HIV

Editor's pick
BETA blog
9 March 2017
Treatment guidelines

Clinical Commissioning Policy: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents

Editor's pick
NHS England
6 March 2017
New & experimental HIV treatments

New nano approach could cut dose of leading HIV treatment in half

Editor's pick
University of Liverpool press release
21 February 2017
Pharmaceutical industry

Merck's lead HIV play hits the mark in first phase 3 challenge

Editor's pick
FierceBiotech
19 February 2017
New & experimental HIV treatments

URMC drug extends effectiveness of HIV therapy

Editor's pick
EurekAlert (press release)
31 January 2017